Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-20.9%
5Y CAGR+33.1%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
-20.9%/yr
Annual compound
5Y CAGR
+33.1%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
4.2x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $62.89M | -45.0% |
| 2024 | $114.33M | -39.3% |
| 2023 | $188.36M | +48.2% |
| 2022 | $127.13M | +226.5% |
| 2021 | $38.93M | +158.5% |
| 2020 | $15.06M | +388.8% |
| 2019 | $3.08M | - |